Who are standard dose of HCQ's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/standard-dose-of-hcq.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

standard dose of HCQ — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

standard dose of HCQ (standard dose of HCQ) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial immunosuppressant. Area: Immunology; Rheumatology.

marketed Antimalarial immunosuppressant Toll-like receptors (TLR7, TLR9); phospholipase C Immunology; Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

standard dose of HCQ (standard dose of HCQ) — University of Sao Paulo General Hospital. Hydroxychloroquine is a quinoline antimalarial that accumulates in lysosomes and inhibits toll-like receptor signaling and antigen presentation, reducing inflammatory and autoimmune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
standard dose of HCQ TARGET	standard dose of HCQ	University of Sao Paulo General Hospital	marketed	Antimalarial immunosuppressant	Toll-like receptors (TLR7, TLR9); phospholipase C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial immunosuppressant class)

University of Sao Paulo General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). standard dose of HCQ — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dose-of-hcq. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab